drugset
drugset / Trial / NCT06533332

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

NCT06533332 ↗

Phase 1 Recruiting 36 enrolled EtiraRx Australia Pty Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Timeline

Start
2024-10-14
Primary completion
2026-12-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ERX-315 Unknown 0.4 mg/kg Intravenous

Indications

breast cancer endometrial cancer liver cancer malignant pancreatic neoplasm ovarian cancer